CLINICAL_TRIALS
trial_result
· 2025-03-27
Clinical Trial Update: Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS [Phase 3]
Summary
Termination of a Phase 3 extension study of oral edaravone in amyotrophic lateral sclerosis has been announced. Results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Tanabe Pharma America, Inc. | Conditions: ALS | Phase 3 | Status: TERMINATED | Results posted: 2025-03-27